Introduction
Extensive studies by Ishizaka (1) have demonstrated the existence of rat T cell factors which have affinity for homologous IgE and which selectively regulate the IgE response. Rat IgE binding factors consist of two activities: IgE-potentiating factors (2) and IgE-suppressive factors (3) . IgE potentiating factors are secreted by T cells from rats subjected to immunization regimens which are favorable for the formation of IgE antibodies whereas IgEsuppressive factors are secreted by T cells from rats immunized under conditions which favor IgG but not IgE responses. Both factors had a molecular weight of -15,000 but differed in their carbohydrate content. The IgE-potentiating factor(s) had affinity for lentil lectin and concanavalin A (Con A). The IgE-suppressive factor failed to bind to the lectins but had affinity for peanut group of investigators revealed that human T lymphocytes activated during the course of a mixed lymphocyte reaction, as well as normal human T cells that proliferated in the presence of interleukin 2 formed IgE-binding factors upon incubation with IgE (5) . IgE-binding factors were also detected in the serum of patients with atopic dermatitis (1) . The functional activity of these human IgE-binding factors have not, to date, been reported.
Our laboratory has used the hyper IgE syndrome (HIE) as a disease model for the study of human IgE synthesis. These patients have extremely high IgE levels (6, 7) and their circulating T cells spontaneously secrete soluble factors which potentiate IgE synthesis (8, 9) . Furthermore, long-term T cell lines bearing Fc receptors for IgE from patients with HIE enhance IgE synthesis via the production of IgE-binding factors (10) . The potential in vivo significance of human IgE-binding factors is suggested by our recent observation that sera from nonatopic individuals contain low molecular weight IgE-binding factors which suppress IgE but not IgG synthesis in vitro (1 1) . Human IgE suppressor factor had minimal affinity for lentil lectin but bound to PNA. Kishimoto and co-workers (12) have also reported the secretion of human IgE-binding factors that selectively suppress human IgE synthesis by lymphocytes from individuals infected with the tubercle bacillus.
The aim of the present investigation was to determine whether circulating IgE-binding factors 
Methods
Plasma samples. Plasma was obtained from four patients with the HIE and three nonatopic controls (serum IgE < 20 IU/ml). The diagnosis of HIE was based on a history of recurrent sinopulmonary infections and skin abscesses predominantly with Staphylococcus aureus, chronic eczematoid dermatitis, and marked elevations of serum IgE ranging from 24,000 to 120,000 IU/ml. Plasma was collected in the presence of a 1:20 dilution of a proteolytic enzyme inhibitor cocktail (100 mM phenylmethyl sulfonyl fluoride, 100 mM benzamidine, 100 mM NaEDTA, and 0.1% Na azide) and centrifuged three times through Diaflo CF50A membranes (Amicon Corp., Lexington, MA) to obtain plasma filtrates free of IgE (< 150 pg IgE/ml). To obtain sufficient IgE-binding factor(s) for Sephadex G-75 gel filtration studies (see below), it was necessary to use plasma obtained during the plasmapheresis of HIE patient no. 2 (Table II) . 200 ml from the initial plasmapheresis was used for these studies. This patient was undergoing a course of plasmapheresis for treatment of complications (blindness due to recurrent corneal ulcerations and severe recurrent infections) from her underlying disease since plasma exchange has been found to transiently correct many of the immunologic abnormalities and reverse the tissue inflammation associated with this disease (13) . The plasmapheresis was done with full knowledge and approval of the Human Investigations Committee at Children's Hospital, Boston, and with the informed consent of the patient and her parents.
Isolation ofIgE-binding factors. The IgE-binding factors in plasma filtrates were isolated by absorption to IgE immobilized to Sepharose, which was prepared by coupling 10 mg of purified human IgE (P.S.) (a kind gift of Dr. K. Ishizaka, Johns Hopkins University, Baltimore, MD) to 2 ml of Sepharose 4B CNBr-activated beads (Pharmacia Fine Chemicals, Piscataway, NJ). A 5-ml aliquot of plasma filtrate was continuously cycled through 1 ml ofIgE-Sepharose packed in a small column by using a peristaltic pump (LKB, Stockholm, Sweden) which connected the effluent tubing into the head ofthe column. After 20 h ofcontinuous cycling at 40C, the effluent supernatants were collected; and the beads were then washed with 50 ml of phosphate-buffered saline (PBS)-0.05 M a-lactose to remove nonspecifically absorbed proteins, and then, eluted with 0.1 M glycine-HCL buffer, pH 3.0, at 40C. Eluates were collected into tubes that contained an appropriate volume of 0.1 M Tris-HCl buffer, pH 8.6, so that the final pH of the eluate was between pH 7.0 and 8.0. Eluates were dialyzed against RPMI-1640 medium and then concentrated to their original plasma filtrate volume.
Fractionation ofIgE-binding factors. IgE-binding factors from HIE plasma filtrates were fractionated by gel filtration through a Sephadex G75 column (Pharmacia; Uppsala, Sweden) (1.5 X 95 cm). The column was calibrated with bovine serum albumin (68,000 D), ovalbumin (48,000 D), chymotrypsinogen (25,000 D), and ribonuclease A (12,800 D). IgEbinding factor preparations were concentrated 100-fold by ultrafiltration through a YM2 Amicon membrane (Amicon Corp.), and a 1-ml sample was applied to the Sephadex column in the presence of bovine serum albumin. The column was eluted with PBS and 2-ml fractions were collected.
In some experiments, plasma-derived IgE-binding factors were fractionated on lectin-coupled Sepharose (Pharmacia, Piscataway, NJ), as previously described (1 1). Con A-Sepharose and agarose coupled with PNA were purchased from Pharmacia Fine Chemicals and Sigma Chemical Co., respectively. IgE binding factor preparations were concentrated 10-fold and 5 ml of the concentrated material were absorbed with I ml Con A-Sepharose or PNA-agarose overnight at 4°C. After recovering the effluent supernatants, the beads were washed extensively with PBS. Con A-Sepharose was eluted with 5 ml 0.2 M a-methyl-Dmannoside whereas PNA-agarose was eluted with 5 ml 0.1 M D-galactose (1 1). The effluent and eluate fractions were dialyzed against RPMI-1640 medium and adjusted to their original volumes before testing for IgEpotentiating activity.
Radioimmunoassay (RIA)for IgE. Duplicate samples from each culture were analyzed for their IgE content. The RIA for IgE was performed in flexible flat-bottom microtiter plates (Cooke Laboratory Products, Alexandria, VA). The wells were filled with 0.1 ml ofa 10 ug/ml solution ofa 1:1 mixture oftwo monoclonal antihuman IgE Fc-specific antibodies. These two antibodies (nos. 8 and 9) were a kind gift of Dr. Siraganian, National Institutes of Health, Bethesda, MD). After incubation for 16 h, the coating solution was removed, and the wells were washed and blocked with 10% horse serum (HS) in PBS for 2 h. After washing 3 times with PBS containing 1% HS, 0.1 ml of culture supernatant or of IgE standard was added to each of the triplicate wells and incubated for 16 h in a humidified chamber at room temperature. The wells were then washed 2 times with PBS-1% HS containing 0.5% Tween 20 and twice with PBS-1% HS, and then 0. 
Results
Presence ofIgE-bindingfactors in plasma filtrates. Table I shows that plasma filtrates from the four patients with HIE inhibited rosette formation of FcR(+) RPMI 8866 cells with E'-IgE by 56, 71, 48, and 35%, respectively. The affinity of this rosetteinhibiting activity for IgE was then examined by absorbing plasma filtrates from each donor with human IgE-Sepharose and recovering the IgE-binding factor(s) by elution with glycine buffer, pH 3. Rosette-inhibiting activity was lost following absorption with human IgE-Sepharose beads and was recovered in the eluates from these beads ( Table I) . Absorption of HIE plasma filtrates over human IgG-Sepharose did not result in loss of activity and eluates from these beads were devoid of rosette inhibition capacity.
These results suggest that the rosette-inhibiting activity of HIE plasma was due to the presence of IgE-binding factors.
Enhancement Tables I and II) .
In Table II The effect of IgE-binding factors from patient 2 was studied on a panel ofB cells obtained from seven normal subjects (serum IgE < 20 IU/ml) and from three patients with seasonal ragweed or grass-induced allergic rhinitis (SAR) during and 6 mo after pollen exposure. Fig. 1 original plasma filtrate volume; and tested for its effect at a final dilution of 1:10 on IgE production by B cells from the two patients with allergic rhinitis. The results shown in Fig. 2 A and B indicate that all of the IgE-potentiating activity as well as most rosette inhibitory activity found in HIE plasma 2 and HIE plasma 3 bound to Con ASepharose and was recovered by elution with a-methyl-D-mannoside. The Con A eluate from HIE plasma 2 caused a fourfold enhancement of IgE synthesis (P < 0.001) and the Con A eluate from HIE plasma 3 caused a fivefold enhancement of IgE synthesis (P < 0.01). In contrast, the IgE-potentiating activity failed to bind to PNA-agarose. Fig. 2 C shows results of the lectin column fractionation from HIE patient 4 whose unfractionated IgE-binding factors had no significant IgE-enhancing activity. Following fractionation over Con A-Sepharose, the Con A effluent caused 80% (Table II) suppression of spontaneous IgE production by B cells from the allergic rhinitis patient (P < 0.01). In contrast, the Con A-Sepharose eluate caused a twofold enhancement of net IgE production (P < 0.01) by the same B cells. The rosette inhibition assay revealed similar levels of IgE-binding factor in both the Con A effluent and Con A eluate fractions of patient 4. Conversely, IgE-enhancing activity from HIE patient no. 4's plasma was observed in the effluent from PNA-Sepharose whereas IgE-suppressor activity was found in the eluate ofPNASepharose. These results indicate that IgE binding factors from patient no. 4 contained a mixture of IgE-suppressive and IgEenhancing activity, the combination ofwhich had no significant effect on IgE synthesis.
The molecular mass of the IgE-potentiating factors was estimated by gel filtration through a Sephadex G-75 column. Plasma IgE-binding factors purified from HIE patient 2 (Table  II) In the present study, the human IgE-enhancing activity from HIE plasma shared several physiochemical characteristics with the rat T cell-derived IgE-potentiating factor described by Yodoi et al. (4) . Human IgE-enhancing activity had marked affinity for Con A but only minimal affinity for PNA. These results suggest that human IgE-potentiating factor contains N-linked, mannose-rich oligosaccharide. Gel filtration of IgE-binding factors from HIE plasma through a Sephadex G-75 column followed by biologic assay of each fraction revealed two peaks of IgEenhancing activity: one with a molecular size of 15,000 D, the other with a molecular size of 60,000 D. The detection of a 60,000 D IgE-binding factor despite filtration ofplasma through CF50A membranes three times was not surprising because although IgE could not be detected in the plasma filtrates, substantial amounts of serum albumin passed through the CF50A membranes (Leung and Geha, unpublished observations). Rat IgE-binding factors of 15,000, 30,000, and 60,000 D have been described by Ishizaka and co-workers (3, 20) . The latter investigators have suggested that the higher molecular size IgE-binding factor may be cleaved to yield the 15,000 molecular size IgEbinding factor. Preliminary investigations in our laboratory indicate that FcER(+) T cell lines from patients with HIE secrete IgE-potentiating factors with a molecular size of 15,000 and 60,000 D (21) . Studies are currently in progress to determine the relationship between these two molecules.
In conclusion, we have demonstrated circulating IgE-binding factors which potentiate IgE synthesis in the plasma of patients with HIE. In contrast, IgE-binding factors from nonatopic sera contain predominantly IgE-suppressive activity (1 1). These results suggest that IgE-binding factors play an important role in the in vivo regulation of human IgE synthesis.
